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Abstract
In this study, an easy to use measurement method was devel-
oped to quantify the balloon dilatation catheters visibility, thus 
making them comparable. The visibility of the distal and prox-
imal markers and the balloon (average values of the markers) 
was determined for fourteen balloons of the same type and 
material, but different lengths and diameters. Repeatability of 
these values was tested by one volunteer and reproducibility 
by two volunteers three times each for all the balloons used 
for the study. It was found that the average visibility for bal-
loons was 12±2%, 13±2% for distal markers, and 13±2% for 
proximal markers. Values of distal and proximal markers did 
not represent significant difference (p=0.20). There was no 
significant difference determined for repeatability and repro-
ducibility either (p values were between 0.71-0.93). Hence, the 
developed measurement method was repeatable and reproduc-
ible making it suitable for comparison of the balloon dilata-
tion catheters based on visibility.
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1 Introduction
Cardiovascular diseases are the number one cause of death 
worldwide. 41% of death is caused by ischaemic heart disease 
and 35% by stroke [1]. These emergences are caused by ste-
nosis or occlusion of the vessels in the heart or brain [2]. One 
of the potential medical devices used for the dilatation of the 
vascular system is the balloon dilatation catheter [3].
The balloon dilatation catheter (so called balloon catheter 
[4-5]) is an intravascular catheter (single or multilumen tube), 
on which a balloon is located near the distal end (this end is 
introduced into the body). The hydraulic dilatation of this bal-
loon dilates the narrowed, occluded vessel [3,6,7]. The balloon 
is monitored in the body using X-ray fluoroscopy [9-10].
The current standard for balloon dilatation catheters (ISO 
10555-1:2013, ISO 10555-4:2013) and the guide of the U.S. 
Food and Drug Administration (FDA) specify that the bal-
loon shall be radio-detectable when it is inserted into the body 
[3,6,11]. The placement of the balloon to the target place in the 
patient’s vasculature is facilitated with radiopaque material. 
This radiopaque material is typically a metal marker band. It 
may be placed on the centre of the balloon (single metal marker) 
or on the ends of the balloon (double metal marker) [12,13].
In the standard for general requirements of the intravascu-
lar catheters (ISO 10555-1:2013), Part 4 relates to the balloon 
dilatation catheters, and requests the test method of visibility 
according to the standard ASTM F640-12 [3,6,14]. It contains 
standard test methods for determining radiopacity however; it 
does not specify the type of the medical devices. The guide of 
the FDA indicates that the radiopaque markers on the balloon 
should be investigated [11,14,15], but unified measure method 
is not recommended in the standards and literature. The manu-
facturer can measure this visibility by different methods, there-
fore they are not comparable. The methods of the manufacturer 
are not available. According to the standard (ASTM F640-12) 
pixel density or optical density are determined by some method.
The measured visibility values are not quantified; instead of 
terms were used for visibility’s characterisation, such as: excel-
lent [16], optimal radiopacity [17], optimal visibility [18], and 
increased radiopacity [19], extremely visible [20].
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The aim of this study was to develop an easy to use meas-
urement method for the objective determination of the balloon 
catheters’ visibility based on the standard ASTM F640-12, the 
FDA and our earlier studies [11,14,21]. This method is suitable 
for quantifying, classifying, and comparing the balloon cath-
eters based on this property. By this method established which 
marker material, which balloon is better visible than the others.
2 Materials and methods
The measurement method developed by us was tested on 
fourteen balloon catheters with same material (polymer bal-
loon with two platinum iridium markers), but different length 
and diameter (Table 1) to determine the dependence of the vis-
ibility on the balloon length and diameter in case of our method.


















The visibility of the radiopaque markers on the balloon was 
determined according to the current standard for balloon dilata-
tion catheters (ISO 10555-4:2013) and the recommendation of 
the FDA [3,9].
X-ray images of the balloons were taken by Dage XiDAT 
XD6600 X-ray Inspection System. The parameters were 
adjusted to the ones used during clinical practice (beam voltage 
of 90-110 kV; cathode power set at 1.19-1.20 W and an average 
frame rate of 32 frames/sec) (Fig. 1a).
The greyscale images of the two markers (Fig. 1b-1c) and 
some parts of the background (Fig. 1d), which did not contain 
the balloon catheter but located close to the balloon or marker, 
were taken using an image-editing program (Gimp 2). During 
X-ray imaging base detector- errors may occur. If the comparable 
images are close to each other, these errors can manifest similarly.
The background of the balloon was the background of the 
sample holder of the X-ray Inspection System, which was the 
same for all balloons. Hence the measured visibility values were 
comparable.
Using software developed the research group to which I 
belong to, the visibility curve of the cut-out greyscale images 
from each marker and from the background was determined 
(Table 2). Then the ratio of double integral curves of the back-
ground and the marker was calculated by the software. The 
value resulted by the image analysis software was the visibility 
of the marker against the background. The average of the two 
markers’ value is the balloon’s visibility; it characterizes the 
visibility of the balloon catheter. The operating principle of the 
image analysis software and the determination of the param-
eters to compare images are described in Ring’s work [21].

















The visibility was placed on a scale from 0 to 100%. If the 
value was ‘0’, the marker was invisible. As the value increased, 
the visibility increased.
Statistical analysis
A region from the background was selected by a volunteer 
and its visibility was determined and compared to those of the 
distal markers (closer to the tip), the proximal markers (fur-
ther from the tip) and the balloon catheter. The average and 
standard deviation of visibility was calculated separately for 
each of the fourteen balloons and distal and proximal markers 
(the average of the two marker values characterizes the visibil-
ity of the balloon catheter). From these values calculated, the 
relative standard deviation (so called coefficient of variation, 
which is the ratio of the standard deviation to average value) 
was obtained. If the obtained value was between 0 and 0.1, 
it indicated homogeneity, between 0.1 and 0.2 indicated low 
heterogeneity, between 0.2 and 0.3 meant higher heterogeneity 
and those from 0.3 to 1.0 meant highly volatile. The smaller the 
value, the more homogeneous the sample was, thus the meas-
urement method was more reliable. The average values were 
compared using statistical tests. For two sample groups Mann–
Whitney–Wilcoxon test and for three sample groups Kruskal-
Wallis test was applied. Both these tests were non-parametrical 
Fig. 1 a) X-ray microscopic image from the balloon marked parts of the 
sample: the cut-out segment from b) the distal marker (it is closer to the tip), 
c) the proximal marker (it is further from the tip), d) and the background
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tests, meaning it was not used for normal distribution of the 
samples. If the p value of the probe is less than 0.05, so the 
significance level is below 5%, the compared groups are sig-
nificantly different. Above this value, the samples did not differ 
significantly from each other.
Repeatability and Reproducibility
To determine the repeatability of the measurement method 
(the variation of the measured data caused by the replace with 
the background), one person measured three different random 
background segments for all the fourteen balloon catheters. To 
determine the reproducibility (the variation of the measured 
data caused by the volunteer who conducted the measurement), 
two volunteers performed the measurement with three different 
background segments each for all the fourteen balloon cathe-
ters. The average values of both the distal and proximal markers 
and the average of the balloon (which characterised the balloon 
catheter’s visibility), and their coefficients of variation were cal-
culated. These values were compared using the same statistical 
tests mentioned in the previous section (Statistical analysis).
3 Results
The average visibility measurements conducted by the first 
volunteer were 12±2% (CV=0.16) for all the fourteen dis-
tal markers, 13±2% (CV=0.18) for all the fourteen proximal 
markers and 13±2% (CV=0.17) for the balloon catheters. The 
values of the coefficient of variation showed low heterogene-
ity (0.1<CV<0.2), therefore, the measurement method was 
acceptable. The average visibility of the distal and the proxi-
mal marker did not differ significantly neither from each other 
(p=0.2), nor from the average values of the balloon (p=0.94).
Repeatability
Three series of measurements were performed by the first vol-
unteer (the markers’ visibility was compared to three different 
background segments). The average visibility of the distal mark-
ers compared with the first background segment was 12±2% 
(CV=0.16); 12±2% (CV=0.15) with the second background seg-
ment; 12±1% (CV=0.13) with the third background segment.
The average visibility of the proximal markers compared 
with the first background segment was 13±2% (CV=0.18); 
13±2% (CV=0.18) with the second background segment; 
13±2% (CV=0.13) with the third background segment.
The average visibility of the balloons was 13±2% (CV=0.17) 
in case of first measurement; 12±2% (CV=0.16) in case of second 
measurement; 12±2% (CV=0.12) in case of third measurement.
The three series of measurements did not show significant 
difference for the values obtained for the distal marker (p=0.88), 
the proximal marker (p=0.93), and the balloon (p=0.87).
The values of the coefficient of variation were between 
0.1 and 0.2 (which meant low heterogeneity) for all series of 
measurements. Therefore, the three visibilities could be aver-
aged in all cases (distal marker, proximal marker and balloon). 
Significant difference was detect neither between the average 
visibility of the distal and proximal markers (p=0.06), nor 
between the markers and balloons (p=0.91).
Due to coefficient of variation insignificant differences, the 
new developed measurement method was repeatable.
Reproducibility
The average visibility with other three different background 
segments for all the fourteen balloon catheters was determined 
by a second volunteer. The obtained values were averaged (due 
to the low heterogeneity: 0.1<CV<0.2) and were compared to 
the relative visibility measured by the first volunteer. There was 
no significant difference between the values measured by differ-
ent volunteers (pdistalmarker=0.71, pproximalmarker=0.90, pballoon=0.82). 
Therefore, the measurement method was reproducible as well.
4 Discussion
The current standard for balloon catheters (ISO 10555-
1:2013, ISO 10555-4:2013) does not include a measuring 
method for determining, quantifying the visibility. The cur-
rent standard for determining radiopacity (ASTM F640-12) 
for medical use does not contain device specific measuring 
method. We do not know, which part or parts of the device 
must be tested.
In this study an easy to use measuring method was described 
which is suitable to uniformly determine the visibility of the 
balloon catheters, so they become comparable with each other.
The measuring method consists of five steps:
• Making an X-ray microscopic only from the balloon. 
(We can use medical images or laboratory X-ray image 
too.)
• Cutting of the markers and the section (with same param-
eters) of the background from the X- ray image.
• Converting it into greyscale images.
• Comparison of the background and the marker with each 
other by the software.
• Averaging of the markers’ visibility.
This measurement without the picture’s making is maxi-
mum five minutes. This measurement method is easy to learn, 
or easy to follow an instruction guide.
I have determined by statistical analysis that
• the investigation of the distal marker is repeatable;
• the investigation of the proximal marker is repeatable;
• the visibility of the distal marker and proximal marker is 
not significant difference;
• the visibility of the distal marker and proximal marker is 
averaged;
• the mean of the distal and proximal marker can character-
ise the visibility of the balloon;
• this characterisation is available independently from the 
balloon diameter and length;
• the investigation of the mean of the distal and proximal 
markers are repeatable;
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• our method for visibility determination is reproducible. I 
have defined that
• the balloon markers shall be investigated in case of bal-
loon catheters;
• the average visibility of the markers is the visibility of the 
balloon catheters.
Visibility was obtained by my measuring method compared 
to the background on a percent scale from 0% to 100%. If the 
background and the settings of the imaging is the same then the 
visibility is comparable. In my case, the equal background and 
the settings were solved.
In this study the visibility of polymer balloons with two 
platinum iridium markers were determined; they visibilities 
were 13%. In the literature there is not basis for comparison, 
therefore we do not know that it is good or not. Further studies 
are needed on different materials to determine the minimum 
values, and the ‘best’ marker material.
5 Conclusion
We made an easy to use, repeatable and reproducible meas-
urement method, which is suitable to determine the visibility 
of balloon catheters in five steps. We have determined, that the 
average visibility is the balloonmarkers can characterise the 
visibility of the balloon catheter, no need to examine the total 
balloon catheter.
In the near future the visibility of the available balloon dila-
tation catheters will determine by the described measurement 
method. A database will be making from these values and by 
the help of physicians determine the minimum visibility which 
is usable during to angioplasty procedure.
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